AKTS Aktis Oncology, Inc. Insider Trading

10% Owner Gadicke Ansbert buys 1,112,777 shares (1.11M) of AKTS at $18.00 for $20,029,986; 5-insider cluster buy within 14 days

Gadicke Ansbert, a 10% owner, purchased 1,112,777 shares at $18.00 on 2026-01-12, increasing his holdings from 9,147,287 shares to 10,260,064 shares (+12.2% vs pre-transaction holdings). This transaction occurred at $18.00, 13.5% below the current market price of $20.81 just two trading days later, though AKTS only listed 4 trading days ago and 52-week metrics lack meaningful context. A cluster pattern shows 5 other insiders also bought within the past 14 days, suggesting coordinated accumulation by the insider cohort. The derivative-conversion flagged for this filing indicates this purchase may represent a conversion or exercise of derivative securities; the insider's full position includes securities in Form 4 Table II (not yet populated), so reported holdings should not be interpreted as a total position statement. The concentration of concurrent insider buying and the substantial purchase volume by a major shareholder warrants investor attention to the underlying conviction or signaling intent in the early trading window post-IPO.

10% owner MPM Bioventures 2018 L.P. buys 1,112,777 shares ($20.0M) of AKTS at $18.00 post-IPO; 5 other insiders also bought in 14 days

MPM Bioventures 2018, L.P., a 10% shareholder, deployed $20,029,986.00 to purchase 1,112,777 shares at $18.00 on 2026-01-12, four trading days after AKTS's recent listing. This transaction increased the fund's stake by 12.2% to 10,260,064 shares. The purchase price of $18.00 sits below the current market price of $20.81, establishing a modest unrealized gain on the executed tranche. Notably, this transaction occurs within a cluster pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated confidence from the insider group immediately following the IPO window. The Form 4 contains a derivative-conversion notation; the full economic position may include derivative holdings not yet populated in our database, so the Table I share count alone does not represent the total position. The convergence of post-IPO insider buying across multiple participants is a material signal of support for the IPO valuation.

Director Kim Helen Susan bought 835,000 shares for $15,030,000.00 at $18.00; AKTS stock now trades at $21.75 post-IPO with 5 other insiders buying within 14 days.

Director Kim Helen Susan purchased 835,000 shares (835.0K shares) across 2 separate transactions for a total of $15,030,000.00 at a blended average price of $18.00 on 2026-01-12. The transaction occurred 2 trading days after AKTS listing, with current trading at $21.75. This large-scale purchase is part of a broader insider cluster: 5 other insiders also bought within the past 14 days, establishing a coordinated multi-insider accumulation pattern in the early post-IPO window. The filing involves a derivative-conversion transaction; the director's total economic position extends beyond the Table I shares shown and should not be assessed as a complete position snapshot. Investors should note the synchronized buying momentum across multiple insiders during the earliest trading window.

EcoR1 Capital (Director) bought 2,222,222 shares at $18.00 for $39,999,996.00 on 2026-01-12; 5 other insiders also bought within 14 days

EcoR1 Capital, LLC acquired 2 separate tranches totaling 2,222,222 shares at $18.00 per share for approximately $40.0M on the stock's second trading day following a recent listing. The current price stands at $21.75, representing a 20.8% premium to the transaction price. Notably, a cluster of 5 other insiders also executed purchases within the past 14 days, suggesting coordinated confidence among the insider group at the IPO price point. This filing involves a derivative-conversion transaction; the director's full position extends beyond the Table I holdings shown (347,305 shares post-transaction), requiring review of Table II derivative securities for complete position context.

10% Owner Vida Ventures II acquired 835,000 shares at $18.00 in 2 transactions, converting derivative securities; stock now trading at $21.75.

Vida Ventures II, a 10% owner of Aktis Oncology, purchased 835,000 shares through 2 separate transactions on 2026-01-12 for a total of $15,030,000.00, with a blended average price of $18.00. The transaction represents a derivative conversion—the Form 4 Table II holdings are not yet populated in the database, so the post-transaction holding of 157,387 shares does not represent the insider's total position. The current stock price of $21.75 reflects a gain of approximately $3.75 per share from the transaction price, though given AKTS is a recent listing (2 trading days), this price movement provides limited historical context. Significantly, 5 other insiders also purchased shares within the past 14 days, forming a cluster buy pattern that amplifies the signal of insider appetite at these price levels immediately following the company's listing.